CEACAM5 and non-small cell lung carcinoma: A better OS has been observed in NSCLC patients receiving immunotherapy with a reduction in serum level of carcinoembryonic antigen (CEA) or cytokeratin-19 fragments (CYFRA 21-1) [67,68].